Investors & Media

There are currently no events to display.

Company Profile

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan, Canada and Brazil for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen , an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Volanesorsen filings for marketing approval have been submitted in the U.S., EU and Canada. Inotersen is progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that TEGSEDI TM (inotersen) has received marketing authorization approval
Toggle Summary New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life- -Akcea prepared for launch following approval- CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc.
Toggle Summary Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
CARLSBAD, Calif. , June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Damien McDevitt , Ph.D. has joined the company as chief business officer. In his role, Dr. McDevitt will serve as a member of Ionis' executive leadership team and will provide strategic
Toggle Summary Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases
CARLSBAD, Calif. , June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it closed its expanded strategic collaboration with Biogen (Nasdaq: BIIB) to discover and develop novel antisense drugs for a broad range of neurological diseases following receipt of

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright Nasdaq. Minimum 15 minutes delayed.

©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.